Sorafenib

75 interactions 4 explained in plain English
Also sold as: Nexavar Nexavar®
About Sorafenib

Sorafenib is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys). Sorafenib is also used to treat hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery and a certain type of thyroid cancer that has spread to other parts of the body and cannot be… Read the full Sorafenib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Felbamate Sertraline Levofloxacin Injection Eribulin Injection Oxaliplatin Injection
1 Contraindicated 68 Major 6 Moderate
All (75) Contraindicated (1) Major (68) Moderate (6)

Major

Sorafenib Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Sorafenib Ifosfamide Injection Ifex Decreased ifosfamide effectiveness Details Sorafenib Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Sorafenib Ivabradine Corlanor Increased risk of QT prolongation Details Sorafenib Lefamulin Xenleta Increased risk of QT interval prolongation Details Sorafenib Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Sorafenib Levofloxacin Levaquin Increased risk of QT interval prolongation Details Sorafenib Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Sorafenib Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Sorafenib Mefloquine Lariam® An increased risk of QT interval prolongation Details Sorafenib Meloxicam Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Sorafenib Meloxicam Injection Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Sorafenib Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Sorafenib Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Sorafenib Methotrexate Injection Abitrexate® Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Sorafenib Metronidazole Flagyl An increased risk of QT interval prolongation Details Sorafenib Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Sorafenib Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Sorafenib Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Sorafenib Moxifloxacin Avelox Increased risk of QT interval prolongation Details Sorafenib Moxifloxacin Injection Avelox Increased risk of QT interval prolongation Details Sorafenib Moxifloxacin Ophthalmic Moxeza® Increased risk of QT interval prolongation Details Sorafenib Octreotide Bynfezia An increased risk of QT interval prolongation Details Sorafenib Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Sorafenib Ofloxacin Floxin® An increased risk of QT interval prolongation Details Sorafenib Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Sorafenib Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Sorafenib Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Sorafenib Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation Details

Moderate

Sorafenib Dexamethasone Injection Decadron Decreased sorafenib concentrations Details Sorafenib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Decreased sorafenib concentrations Details Sorafenib Docetaxel Beizray Increased docetaxel exposure and plasma concentrations Details Sorafenib Docetaxel Injection Beizray Increased docetaxel exposure and plasma concentrations Details Sorafenib Doxorubicin Adriamycin Increased exposure to DOXOrubicin Details Sorafenib Levothyroxine Ermeza Increased risk of hypothyroidism Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.